GLYC

Glycomimetics

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 1

consensus rating "Buy"

EPS Beats Expectation

Revenue Keeps Dropping

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About GLYC

Glycomimetics, Inc.

A late clinical-stage biotechnology company that developing glycobiology-based therapies for cancers and inflammatory diseases

Industry

Biological Technology

Established Date

Invalid Date

Listing Date

01/10/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.glycomimetics.com

Security Type

Common stock

Office address

9708 Medical Center Drive , Rockville , Maryland 20850

Business

Introduction

Founded in Delaware in 2003, Glycomimetics, Inc., is a late-stage clinical biotechnology company dedicated to improving the lives of patients with cancer and inflammatory diseases by inhibiting carbohydrate interactions that occur on the cell surface. The company is developing a proprietary pipeline of sugar mimics, small molecules that mimic the structure of carbohydrates and are involved in important biological processes that inhibit carbohydrate disease-related functions.

Company Financials

EPS

GLYC has released its 2024 Q1 earnings. EPS was reported at -0.17, versus the expected -0.16, missing expectations. The chart below visualizes how GLYC has performed over recent quarters, highlighting trends in earnings surprises.